Business
Kane Biotech Receives Health Canada Approval for revyve® Antimicrobial Wound Gel Spray
WINNIPEG, Manitoba, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane...
About this update from Kane Biotech Inc.
[{"type":"text","content":"Kane Biotech Receives Health Canada Approval for revyve® Antimicrobial Wound Gel Spray\n\n\n\n WINNIPEG, Manitoba, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces that Health Canada has approved its revyve\n \n ®\n \n Antimicrobial Wound Gel Spray for use in Canada.\n \n\n\n\n\n\n\n Health Canada approved revyve Antimicrobial Wound Gel Spray\n \n\n\n revyve Antimicrobial Wound Gel Spray has been previously cleared under the FDA 510(k) process. This Health Canada approval represents another regulatory milestone for Kane and the Company’s commitment to advancing wound care innovation in Canada. The revyve Antimicrobial Wound Gel Spray is designed to support clinicians in managing complex wounds by helping to reduce microbial burden and promote a healthier wound environment.\n \n\n Health Canada approval provides clinicians and patients in Canada with access to a new wound care option for managing burns, large surface area wounds and ulcers. The spray is part of Kane Biotech’s revyve wound care portfolio, which has been evaluated in multiple clinical settings in the United States.\n \n\n Dr. Robert B. Huizinga, Interim CEO of Kane Biotech, commented, “Health Canada’s approval of the revyve Antimicrobial Wound Gel Spray is another step forward in our mission to improve outcomes for patients with chronic and hard-to-heal wounds. This approval validates the strength of our clinical data and provides Canadian healthcare providers with a new tool to address the burden of wound infections.”\n \n\n The Company will work closely with healthcare partners and distributors to ensure appropriate access and education around the use of revyve Antimicrobial Wound Gel Spray. Kane Biotech continues to advance its wound care portfolio, including the recent FDA submission of revyve Antimicrobial Wound and Skin Cleanser as the Company’s third product in its revyve product line.\n \n\n\n About Kane Biotech Inc. (TSX-V: KNE)\n \n\n\n Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds which results in serious clinical outcomes and significant cost. revyve\n...